DK1240326T3 - Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor - Google Patents

Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor

Info

Publication number
DK1240326T3
DK1240326T3 DK00989877T DK00989877T DK1240326T3 DK 1240326 T3 DK1240326 T3 DK 1240326T3 DK 00989877 T DK00989877 T DK 00989877T DK 00989877 T DK00989877 T DK 00989877T DK 1240326 T3 DK1240326 T3 DK 1240326T3
Authority
DK
Denmark
Prior art keywords
receptor
antibodies
identify
killer cells
involved
Prior art date
Application number
DK00989877T
Other languages
Danish (da)
English (en)
Inventor
Alessandro Moretta
Cristina Bottino
Roberto Biassoni
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2288307A external-priority patent/CA2288307C/en
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Application granted granted Critical
Publication of DK1240326T3 publication Critical patent/DK1240326T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00989877T 1999-11-15 2000-11-15 Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor DK1240326T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44051499A 1999-11-15 1999-11-15
CA2288307A CA2288307C (en) 1999-11-15 1999-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
PCT/EP2000/011697 WO2001036630A2 (en) 1999-11-15 2000-11-15 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Publications (1)

Publication Number Publication Date
DK1240326T3 true DK1240326T3 (da) 2009-06-02

Family

ID=25681295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00989877T DK1240326T3 (da) 1999-11-15 2000-11-15 Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor

Country Status (8)

Country Link
EP (1) EP1240326B1 (https=)
JP (1) JP4776845B2 (https=)
AT (1) ATE423848T1 (https=)
AU (1) AU783899B2 (https=)
DE (1) DE60041655D1 (https=)
DK (1) DK1240326T3 (https=)
ES (1) ES2321687T3 (https=)
WO (1) WO2001036630A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP1575615A1 (en) * 2002-12-23 2005-09-21 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
HRP20170342T1 (hr) 2003-07-24 2017-05-19 Innate Pharma S.A. Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
US20070178106A1 (en) * 2004-04-30 2007-08-02 Innate Pharma, S.A. Compositions and methods for enhancing nk cell activity
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
DK1773884T3 (da) 2004-08-03 2012-05-21 Innate Pharma Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
EP1626059A1 (en) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
CN102099055A (zh) * 2007-10-04 2011-06-15 津莫吉尼蒂克斯公司 B7家族成员zB7H6及相关的组合物和方法
US10736963B2 (en) * 2015-07-24 2020-08-11 Innate Pharma Methods for detecting tissue infiltrating NK cells
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20250051440A1 (en) 2021-12-14 2025-02-13 Institut National de la Santé et de la Recherche Médicale Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP7821427B2 (ja) * 2022-01-27 2026-02-27 学校法人 東洋大学 ナチュラルキラー細胞活性の測定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170352A1 (en) * 1993-08-27 1995-03-02 Paul Anderson Natural killer cell-specific antigen and antibodies that identify the same
WO1999023867A2 (en) * 1997-11-07 1999-05-20 Biogen, Inc. Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use
WO1999049881A2 (de) * 1998-03-27 1999-10-07 Gabriele Multhoff Verwendung von hsp70 protein

Also Published As

Publication number Publication date
JP4776845B2 (ja) 2011-09-21
WO2001036630A9 (en) 2002-09-19
JP2003523735A (ja) 2003-08-12
WO2001036630A2 (en) 2001-05-25
AU783899B2 (en) 2005-12-22
DE60041655D1 (de) 2009-04-09
ATE423848T1 (de) 2009-03-15
EP1240326A2 (en) 2002-09-18
AU2667701A (en) 2001-05-30
EP1240326B1 (en) 2009-02-25
WO2001036630A3 (en) 2001-11-08
ES2321687T3 (es) 2009-06-10

Similar Documents

Publication Publication Date Title
DK1240326T3 (da) Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
DK1673397T3 (da) Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
SE0301653D0 (sv) Novel compounds
ATE279517T1 (de) Il-17 receptor
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ES2246567T3 (es) Composiciones para receptores inhibidores de celulas t y usos de las mismas.
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
PT1506185E (pt) Compostos novos e sua utilizacao
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
BRPI0413676A (pt) composto, e, composição farmacêutica
IL164464A0 (en) Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use
EA200601759A1 (ru) Композиции рамиприла
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
NZ514696A (en) IL-8 receptor antagonists
MX9204613A (es) Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren